XSHE
300760
Market cap28bUSD
Sep 17, Last price
156.80CNY
1D
-0.78%
1Q
11.99%
IPO
102.85%
Name
Shenzhen Mindray Bio-Medical Electronics Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating on a global scale, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. specializes in providing a comprehensive range of medical devices and innovative healthcare solutions. Its extensive portfolio encompasses several key segments. Within patient monitoring and life support, the company manufactures crucial equipment such as patient monitoring systems, electrocardiographs, defibrillators, anesthesia machines, ventilators, infusion pumps, surgical lights, operating tables, medical supply units, and endoscopes, along with associated accessories. This segment also delivers integrated solutions for emergency care, peri-operative management, critical care, and medical IT systems. For in-vitro diagnostics, Mindray offers sophisticated products including hematology and chemistry analyzers and their reagents, chemiluminescence immunoassay products, hemoglobin systems, flow cytometry instruments, and microplate readers and washers. These are further supported by solutions tailored for coagulation, urinalysis, and microbiology. The company additionally produces advanced medical imaging systems, covering both ultrasound and radiology products, and supplies a dedicated line of veterinary products. Founded in 1991, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. maintains its primary operational base in Shenzhen, People's Republic of China.
Key people
Yun Zhao
Finance Director · since 2019
Haitao Huang
Deputy General Manager · since 2019
Deputy General Manager · since 2019
Hao Wu
Executive Deputy General Manager, Director · since 2019
Wenmei Li
Secretary of the Board · since 2019
Minghe Cheng
General Manager, Director · since 2019
Yanmei Guo
Deputy General Manager, Director · since 2019
Xiting Li
Chairman of the Board · since 2019
Hang Xu
Director · since 2019
Qiyao Wu
Independent Director · since 2019
Hao Xi
Independent Director · since 2019
Independent Director · since 2019
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||